Evidence map›Paper›PMID 35494430›Full record

ArticleRSC advances2020

Unraveling how the Gly526Ser mutation arrests prostaglandin formation from arachidonic acid catalyzed by cyclooxygenase-2: a combined molecular dynamics and QM/MM study.

Adrián Suñer-Rubio, Anna Cebrián-Prats, Àngels González-Lafont, José M Lluch

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. The role of oxylipins in NSAID-exacerbated respiratory disease (N-ERD).Advances in pharmacology (San Diego, Calif.) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Adrián Suñer-RubioDepartament de Química, Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona Spain JoseMaria.Lluch@uab.cat.ORCID https://orcid.org/0000-0002-6738-0082
Anna Cebrián-PratsDepartament de Química, Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona Spain JoseMaria.Lluch@uab.cat.ORCID https://orcid.org/0000-0001-6974-0670
Àngels González-LafontDepartament de Química, Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona Spain JoseMaria.Lluch@uab.cat.ORCID https://orcid.org/0000-0003-0729-2483
José M LluchDepartament de Química, Universitat Autònoma de Barcelona 08193 Bellaterra Barcelona Spain JoseMaria.Lluch@uab.cat.ORCID https://orcid.org/0000-0002-7536-1869
Universitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclooxygenases (COXs) are the enzymes responsible for the biosynthesis of prostaglandins, eicosanoids that play a major role in many physiological processes. Particularly, prostaglandins are known to trigger inflammation, and COX-2, the enzyme isoform associated with this inflammatory response, catalyzes the cyclooxidation of arachidonic acid, leading to prostaglandin G2. For this reason, COX-2 has been a very important pharmacological target for several decades now. The catalytic mechanism of COX-2, a so-called all-radical mechanism, consists of six chemical steps. One of the most intriguing aspects of this mechanism is how COX-2 manages to control the regio- and stereospecificity of the products formed at each step. Mutagenesis experiments have previously been performed in an attempt to find those hot-spot residues that make such control possible. In this context, it is worth mentioning that in experiments with the Gly526Ser COX-2 mutant, prostaglandins were not detected. In this paper, we have combined molecular dynamics simulations and quantum mechanics/molecular mechanics calculations to analyze how the COX-2 catalytic mechanism is modified in the Gly526Ser mutant. Therefore, this study provides new insights into the COX-2 catalytic function.

Identifiers

PMID35494430
PMCPMC9047453
OpenAlexW2997900863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.